Clinical trial

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib

NCT00802841

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-05-01

PhasePHASE3

Study timeline

Study start (unknown)2009-05-01Date precision: month

Registry last updated2015-11-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Chronic Myelogenous Leukemiaunresolved

Interventions

nilotinibDRUG · verified · RxNorm: nilotinib

imatinibDRUG · verified · RxNorm: imatinib

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

São PauloSão Paulo, Brazil4 Mexico CityMexico City, Mexico4 MoscowRussia2 Saint PetersburgRussia2 BerlinGermany1 BeijingChina1 ShanghaiChina1 KrakowPoland1 NanjingJiangsu, China1 WroclawPoland1 Porto AlegreRio Grande do Sul, Brazil1 ChengduSichuan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00802841 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.